In conclusion, NR3C1 aberrations are relatively rare in newly diagnosed ALL, and although patients with either NR3C1 mutations or deletions have a significantly inferior response to GCs in vitro compared with NR3C1 wild-type patients,53 the response to GCs and the transcriptional activity in ALL patients with NR3C1 alterations is variable. The gene discussed is NR3C1; the disease is acute lymphoblastic leukemia.